201530-44-1

Upstream product

• 109-01-3 1-methyl-piperazine 
• 26189-59-3 1-chloro-1-(dimethylamino)-2-methyl-1-propene 
• 201530-41-8 deferasirox 
• 1218-69-5 2-(2-hydroxyphenyl)-4H-benzo[e][1,3]oxazin-4-one 
• 65-45-2 salicylamide 
• 69-72-7 salicylic acid 

Relevant academic research and scientific papers

In vitrostudies of deferasirox derivatives as potential organelle-targeting traceable anti-cancer therapeutics

We report here strategic functionalization of the FDA approved chelator deferasirox (1) in an effort to produce organelle-targeting iron chelators with enhanced activity against A549 lung cancer cells. Derivative 8 was found to have improved antiproliferative activity relative to 1. Fluorescent cell imaging revealed that compound 8 preferentially localises within the lysosome.

CELL ACTIVATABLE IRON CHELATORS

Provided herein are compounds of the formula (I): wherein the variables are as defined herein. Pharmaceutical compositions of the compounds are also provided. In some aspects, these compounds may be used for the treatment of diseases or disorders, such as

Substituted 3,5-diphenyl-1,2,4-triazoles and their use as pharmaceutical metal chelators

The use is described of 3,5-diphenyl-1,2,4-triazoles of the formula I in which R1-R5are as defined in the description. The compounds have useful pharmaceutical properties and are particularly active as iron chelators. They can be used for the treatment of iron overload in warm-blooded animals.